| [1] |
Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodefi ciency [J] J Immunol, 1994, 153 (4):1687-96.
|
| [2] |
Baker J, Verneris MR, Ito M, et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production [J]. Blood, 20 01, 97(10): 2923-31.
|
| [3] |
Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells [J]. Blood,2004,103(8):3065-72.
|
| [4] |
Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma[J]. Biol Blood Marrow Transplant, 2005, 11(3):181-7.
|
| [5] |
Terao I, Hashimoto S, Horie T. Effect of GM-CSF on TNF-alpha and IL-1-beta production by alveolar macrophages and peripheral blood monocytes from patients with sarcoidosis [J]. Int Arch Allergy Immunol, 1993, 102(3): 242-8.
|
| [6] |
Stavik B, Skretting G, Aasheim HC, et al. Down-regulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility [J]. BMC Cancer,2011,11:357.
|
| [7] |
Pardo J, Balkow S, Anel A, et al. Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control [J]. Eur J Immunol, 2002, 32(10): 2881-7.
|
| [8] |
Metha BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+killer cells [J]. Blood, 19 95, 86(9):3493-9.
|
| [9] |
Grossman WJ, Verbsky JW, Tollefsen BL, et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells[J].Blood,2004,104(9): 2840-8.
|
| [10] |
Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside [J]. J Biomed Biotechnol, 2010,2010:435745.
|
| [11] |
Nishimura R, Baker J, Beilhack A, et al. In vivo traffi cking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity [J]. Blood, 2008, 11 2(6):2563-74.
|
| [12] |
Hontscha C, Borck Y, Zhou H,et al. Clinical trials on CIK cells: fi rst report of the international registry on CIK cells (IRCC) [J]. J Cancer Res Clin Oncol,2011,137(2): 305-10.
|
| [13] |
Zoll B, Lefterova P, Csipai M, et al. Generation of cytokineinduced killer cells using exogenous interleukin-2,-7 or -12 [J]. Cancer Immunol Immunother,1998,47(4): 221-6.
|
| [14] |
Verneris MR, Komacker M, Mailänder V, et al. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis [J].Cancer Immunol Immunother, 2000, 49(6): 335-45.
|
| [15] |
Finker S, Trojaneck B, Lefferova P, et al. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor mediated transfection with the interleukin-7 gene [J]. Gene Ther, 19 98, 5(1): 31-9.
|
| [16] |
Holy C, Bang CD, Chang P, et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo effi cacy in severe combined immunodeficiency disease mice[J]. Blood,1998,92(9): 3318-27.
|
| [17] |
Gütgemann S, Frank S, Strehl J, et al. Cytokine-induced killer cells are type II natural killer T cells [J]. Ger Med Sci, 2007, 5: Doc07.
|
| [18] |
Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity [J]. Nat Med, 2002, 8(6): 56 7-73.
|
| [19] |
Lemos MP, Fan L, Lo D, et al. CD8alpha+ and CD11b+ dendritic cell-restricted MHC class II controls Th1 CD4+ T cell immunity [J] J Immunol, 2003, 171(10): 5077-84.
|
| [20] |
van der Veen RC. Nitric oxide and T helper cell immunity [J]. Int Immunopharmacol, 2001, 1(8): 1491-500.
|
| [21] |
Mita Y,Dobashi K,Endou K,et al. Toll-like receptor 4 surface expression on human monocytes and B cells is modulated by IL-2 and IL-4[J]. Immunol Lett, 2002, 81(1):71-5.
|
| [22] |
Kikuchi T, Crystal RG. Antigen-pulsed dendritic cells expressing macrophage-derived chemokine elicit Th2 responses and promote specifi c humoral immunity[J]. J Clin Invest, 2001,108(6):917-27.
|
| [23] |
Daichou Y, Kurashige S, Hashimoto S, et al. Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients [J] Nephron, 1999, 83(3): 237-45.
|
| [24] |
Minty A, Chalcn P, Deroq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses [J]. Nature, 1993, 362(6417): 248-50.
|
| [25] |
Mckenzie AN, Culpepper JA, de Waal Malefyt R, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function [J]. Prol Natl Acad Sci U S A, 1993, 90 (8): 3735-9.
|
| [26] |
Defrance T, Carayon P, Billian G, et al. Interleukin-13 is a B cell stimulating factor [J]. J Exp Med, 1994, 179(1): 135-43.
|
| [27] |
Morse MA, Lyerly HK, Li Y. The role of IL-13 in generation of dendritic cells in vitro [J]. J Immunother, 1999, 22(6): 506-13.
|
| [28] |
Van Den Berg JG, Aten J, Chand MA, et al. Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells [J]. J Am Soc Nephrol, 2000, 11(3): 413-22.
|
| [29] |
Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation [J]. Blood, 2009, 113(13):3050-8.
|
下载:
